Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Internal Medicine (Tokyo, Japan)|January 15, 2025
Metachronous Pancreatic Cancer with Pancreaticobiliary Maljunction Diagnosed Five Years after Cholecystectomy for Gallbladder Cancer, in Which Follow-up Imaging was Possible Until the Onset of Cancer: A Case Report and Review of the LiteratureMasaki Miyazawa, Masahiro Yanagi, Tomoyoshi Chiba, et al.
Hepatology (Baltimore, Md.)|April 5, 2014
Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinomaTaro Yamashita, Azusa Kitao, Osamu Matsui, et al.
Internal Medicine (Tokyo, Japan)|October 15, 2023
Post-allogeneic Hematopoietic Stem Cell Transplantation Portal Hypertension Not Associated with Liver Cirrhosis, Veno-occlusive Disease, or Graft-versus-host DiseaseMasaki Miyazawa, Masahiro Yanagi, Tomoyoshi Chiba, et al.
Molecular Oncology|April 9, 2021
BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinomaHan Chen, Kouki Nio, Taro Yamashita, et al.
Regenerative Therapy|December 20, 2021
Characterization of adipose tissue-derived stromal cells of mice with nonalcoholic fatty liver disease and their use for liver repairMasaaki Yano, Alessandro Nasti, Akihiro Seki, et al.
JMIR Research Protocols|April 2, 2020
Regenerative Therapy for Liver Cirrhosis Based on Intrahepatic Arterial Infusion of Autologous Subcutaneous Adipose Tissue-Derived Regenerative (Stem) Cells: Protocol for a Confirmatory Multicenter Uncontrolled Clinical TrialYoshio Sakai, Shinya Fukunishi, Masayuki Takamura, et al.
Regenerative Therapy|June 7, 2021
Clinical trial of autologous adipose tissue-derived regenerative (stem) cells therapy for exploration of its safety and efficacyYoshio Sakai, Shinya Fukunishi, Masayuki Takamura, et al.
Hepatology (Baltimore, Md.)|February 20, 2021
Serum Laminin γ2 Monomer as a Diagnostic and Predictive Biomarker for Hepatocellular CarcinomaTaro Yamashita, Naohiko Koshikawa, Tetsuro Shimakami, et al.
Investigational New Drugs|September 11, 2018
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patientsWon Young Tak, Baek-Yeol Ryoo, Ho Yeong Lim, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2023
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)Masato Ozaka, Kohei Nakachi, Satoshi Kobayashi, et al.
Pageof 17